PSG.DE PharmaSGP SE (XETRA) €29.00 26 Feb 2026: Oversold bounce opportunity
At market close on 26 Feb 2026, PSG.DE stock traded at €29.00, unchanged on the session but showing an oversold bounce setup. Volume finished at 12,424, above the average 5,399, which suggests short-term buying interest. We see a tactical entry for traders who want a defined risk, given the proximity to the day low €28.60 and the year high €30.00. Meyka AI’s real-time tools flag the setup as a short-term rebound candidate in a relatively healthy healthcare peer group.
Quick market facts for PSG.DE stock
PSG.DE closed on XETRA at €29.00 with a market cap of €333,862,500.00. The stock opened at €28.80, posted a day low of €28.60, and a day high of €29.00. The company reports EPS €1.68 and a trailing PE near 17.26, below the healthcare sector average PE 30.55.
Why an oversold bounce matters for PSG.DE stock
The oversold bounce trade seeks a short-term rebound after a stretched move lower; PSG.DE shows that setup because volume is 12,424, which is 2.30x the average volume. A higher relative volume on a flat close often precedes mean-reversion toward near-term resistance at €30.00.
Fundamentals and valuation: PSG.DE stock analysis
PharmaSGP reports healthy margins and cash metrics with operating cash flow per share €1.99 and free cash flow per share €1.89. The company shows a strong current ratio 2.68 and negligible net debt, supporting a conservative valuation view despite a price-to-book near 9.12. Revenue growth was 17.55% in FY 2024 and EPS growth 20.44% year over year.
Technical setup and trading triggers for PSG.DE stock
Near-term support sits at the session low €28.60 and at the 50-day average €28.52; resistance is at the year high €30.00. The 200-day average is €26.10, which limits downside in a bounce trade. Traders should set a stop under €28.00 and a first target near €30.00 for a tight risk-reward swing.
Meyka AI grade and PSG.DE stock forecast
Meyka AI rates PSG.DE with a score out of 100: 79.15 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year value of €27.36, a 3-year value of €29.48, and a 5-year value of €31.56. Compared with the current price €29.00, the 1-year model implies -5.66% downside, the 3-year implies +1.64% upside, and the 5-year implies +8.83% upside. Forecasts are model-based projections and not guarantees.
Risks and catalysts for PSG.DE stock
Key risks include inventory days above 400.36, which can pressure working capital, and a high price-to-book near 9.12 that limits margin for valuation errors. Catalysts include stronger export demand in Europe, margin expansion, and any positive product chain news that lifts specialty OTC sales.
Final Thoughts
PSG.DE stock closed XETRA at €29.00 on 26 Feb 2026 and presents a defined oversold bounce trade for tactically-minded investors. Fundamentals show positive cash flow per share €1.99 and EPS €1.68, while valuation via PE 17.26 compares favorably versus the healthcare sector PE 30.55. Meyka AI’s grade is B+ (79.15) — Suggestion: BUY, reflecting healthy margins, low net debt, and solid growth metrics. Meyka AI’s forecast model projects €27.36 in one year and €31.56 in five years, implying a near-term downside risk but multi-year upside. For traders we prefer a stop under €28.00, a near target at €30.00, and a conservative 12-month target aligned with the model at €27.36 only for investors who accept model-based risk. These are data-driven scenarios from an AI-powered market analysis platform and not investment advice. Forecasts are model-based projections and not guarantees.
FAQs
Is PSG.DE stock a buy after the recent session close?
PSG.DE stock shows a tactical oversold bounce setup at €29.00. Meyka AI grades the stock B+ (79.15) with a BUY suggestion, but traders should use a stop under €28.00 and plan targets near €30.00.
What price targets does Meyka AI give for PSG.DE stock?
Meyka AI’s forecast model projects €27.36 in one year, €29.48 in three years, and €31.56 in five years. These are model projections and not guarantees.
What are the main risks for PSG.DE stock?
Main risks include long inventory days 400.36, a high price-to-book 9.12, and any slowdown in European OTC demand. Low net debt softens balance-sheet risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.